icotinib Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 5209 610798-31-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • icotinib
  • icotinib hydrochloride
Icotinib is a new epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that developed and used in China for the treatment of patients with non-small cell lung cancer (NSCLC).
  • Molecular weight: 391.43
  • Formula: C22H21N3O4
  • CLOGP: 4.16
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 1
  • TPSA: 74.73
  • ALOGS: -4.49
  • ROTB: 2

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
None China Food and Drug Administration (CFDA) Zhejiang Beta Pharma Inc.

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EB08 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Non-small cell lung cancer indication 254637007 DOID:3908

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.01 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Epidermal growth factor receptor Kinase INHIBITOR IC50 8.70 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
1204313-51-8 SECONDARY_CAS_RN
C2604307 UMLSCUI
CHEMBL2087361 ChEMBL_ID
CHEMBL4297665 ChEMBL_ID
DB11737 DRUGBANK_ID
C531470 MESH_SUPPLEMENTAL_RECORD_UI
7641 IUPHAR_LIGAND_ID
9G6U5L461Q UNII
22024915 PUBCHEM_CID

Pharmaceutical products:

None